Antiproliferative effect of sulindac in colonic neoplasia prevention: Role of COOH-terminal Src kinase

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 1797-1806

  Kunte, Dhananjay P ^a   Wali, Ramesh K ^a   Koetsier, Jennifer L ^a   Roy, Hemant K ^a,b  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; SULINDAC; SULINDAC SULFIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN TYROSINE KINASE C SRC; PROTEIN-TYROSINE KINASE C-SRC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HT29; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REPRESSION; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RNA VECTOR; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CYCLE; COLON; COLON TUMOR; DOWN REGULATION; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; FISCHER 344 RAT; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; CELL CYCLE; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; HT29 CELLS; HUMANS; MALE; MODELS, BIOLOGICAL; PROTEIN-TYROSINE KINASES; RATS; RATS, INBRED F344; SULINDAC;

EID: 51049124324     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0022     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42.
3. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
4. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:365-75.
5. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 2005;70:969-86.
6. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
7. Wang HM, Zhang GY. Effect of indomethacin on human colorectal cancer cells HCT116 and SW480. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004;29:28-31.
8. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998;95:681-6.
9. Lu D, Cottam HB, Corr M, Carson DA. Repression of β-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2005;102:18567-71.
10. Herrmann C, Block C, Geisen C, et al. Sulindac sulfide inhibits Ras signaling. Oncogene 1998;17:1769-76.
11. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-14.
12. Rice PL, Peters SL, Beard KS, Ahnen DJ. Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther 2006;5:746-54.
13. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
14. Kim JS, Baek SJ, Sali T, Eling TE. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 2005;4:487-93.
15. Pangburn HA, Kraus H, Ahnen DJ, Rice PL. Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. J Carcinog 2005;4:16.
16. Zhang Z, DuBois RN. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 2000;118:1012-7.
17. Irby RB, Mao W, Coppola D, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999;21:187-90.
18. Dehm S, Senger MA, Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 2001;487:367-71.
19. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J Biol Chem 1991;266:24249-52.
20. Nakagawa T, Tanaka S, Suzuki H, et al. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int J Cancer 2000;88:384-91.
21. Kunte DP, Wali RK, Koetsier JL, et al. Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett 2005;579:3497-502.
22. Roy HK, DiBaise JK, Black J, Karolski WJ, Ratashak A, Ansari S. Polyethylene glycol induces apoptosis in HT-29 cells: potential mechanism for chemoprevention of colon cancer. FEBS Lett 2001;496:143-6.
23. Roy HK, Liu Y, Wali RK, et al. Four-dimensional elastic light-scattering fingerprints as preneoplastic markers in the rat model of colon carcinogenesis. Gastroenterology 2004;126:1071-81; discussion 948.
24. Behrens J, Vakaet L, Friis R, et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/β-catenin complex in cells transformed with a temperature sensitive v-SRC gene. J Cell Biol 1993;120:757-66.
25. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin- mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002;62:2669-74.
26. Chen LC, Hao CY, Chiu YS, et al. Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 2004;64:3694-700.
27. Tanaka T, Kojima T, Suzui M, Mori H. Chemoprevention of colon carcinogenesis by the natural product of a simple phenolic compound protocatechuic acid: suppressing effects on tumor development and biomarkers expression of colon tumorigenesis. Cancer Res 1993;53:3908-13.
28. Liang M, Cai T, Tian J, Qu W, Xie ZJ. Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. J Biol Chem 2006;281:19709-19.
29. Pai R, Szabo IL, Giap AQ, Kawanaka H, Tarnawski AS. Nonsteroidal anti-inflammatory drugs inhibit re-epithelialization of wounded gastric monolayers by interfering with actin, Src, FAK, and tensin signaling. Life Sci 2001;69:3055-71.
30. Bernardi A, Jacques-Silva MC, Delgado-Canedo A, Lenz G, Battastini AM. Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines. Eur J Pharmacol 2006;532:214-22.
31. Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest 1994;93:509-15.
32. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004;279:43261-72.
33. Cam WR, Masaki T, Shiratori Y, et al. Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma. Cancer 2001;92:61-70.
34. Rengifo-Cam W, Konishi A, Morishita N, et al. Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis. Oncogene 2004;23:289-97.
35. Pereira MA, Tao L, Wang W, et al. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-α gene in rat colon tumors. Carcinogenesis 2004;25:1917-23.
36. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007;282:5413-9.
37. Sheng G, Bernabe KQ, Guo J, Warner BW. Epidermal growth factor receptor-mediated proliferation of enterocytes requires p21waf1/cip1 expression. Gastroenterology 2006;131:153-64.
38. Yang W, Bancroft L, Augenlicht LH. Methylation in the p21WAF1/cip1 promoter of Apc+/-, p21+/- mice and lack of response to sulindac. Oncogene 2005;24:2104-9.
39. Bock JM, Menon SG, Sinclair LL, et al. Celecoxib toxicity is cell cycle phase specific. Cancer Res 2007;67:3801-8.
40. Yang WC, Mathew J, Velcich A, et al. Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 2001;61:565-9.
41. 2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005;65:8927-35.
42. Brizzi MF, Dentelli P, Gambino R, et al. STAT5 activation induced by diabetic LDL depends on LDL glycation and occurs via src kinase activity. Diabetes 2002;51:3311-7.
43. Mamidipudi V, Dhillon NK, Parman T, Miller LD, Lee KC, Cartwright CA. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene 2007;26:2914-24.
44. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007;128:281-94.
45. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
46. Hinck L, Nathke IS, Papkoff J, Nelson WJ. β-Catenin: a common target for the regulation of cell adhesion by Wnt-1 and Src signaling pathways. Trends Biochem Sci 1994;19:538-42.
47. Zhu F, Choi BY, Ma WY, et al. COOH-terminal Src kinase-mediated c-Jun phosphorylation promotes c-Jun degradation and inhibits cell transformation. Cancer Res 2006;66:5729-36.
48. Chen YX, Fang JY, Lu R, Qiu DK. Expression of p21(WAF1) is related to acetylation of histone H3 in total chromatin in human colorectal cancer. World J Gastroenterol 2007;13:2209-13.
49. Kunte D, Wali RK, Koetsier J, Nyhuis M, Roy HK. C-terminal Src kinase (CSK) induction modulates the pro-apoptotic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in the chemoprevention of colorectal cancer (CRC). Gastroenterology 2007;132:A14.
50. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007;67:3862-70.